Skip to main content
Fig. 2 | Radiation Oncology

Fig. 2

From: Can neoadjuvant chemotherapy improve survival in stage T3-4N1 nasopharyngeal carcinoma? A propensity matched analysis

Fig. 2

The Kaplan-Meier estimates of overall survival (OS), locoregional recurrence-free survival (LRFS), distant recurrence-free survival (DRFS), and recurrence-free survival (RFS) for NCT + CCRT group and CCRT group in selected 170 patients. The median follow-up in NCT + CCRT group and CCRT group were 88 months and 85 months, respectively. Overall survival (a), locoregional recurrence-free survival (b), distant recurrence-free survival (c), and recurrence-free survival (d). P-values were calculated by the unadjusted log–rank test. NCT, neoadjuvant chemotherapy; CCRT, concurrent chemoradiotherapy

Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us